1. bookVolumen 70 (2020): Edición 1 (March 2020)
Detalles de la revista
License
Formato
Revista
eISSN
1846-9558
Primera edición
28 Feb 2007
Calendario de la edición
4 veces al año
Idiomas
Inglés
Acceso abierto

Development and validation of a UPLC-MS method for determination of atazanavir sulfate by the “analytical quality by design” approach

Publicado en línea: 01 Nov 2019
Volumen & Edición: Volumen 70 (2020) - Edición 1 (March 2020)
Páginas: 17 - 33
Aceptado: 20 Mar 2019
Detalles de la revista
License
Formato
Revista
eISSN
1846-9558
Primera edición
28 Feb 2007
Calendario de la edición
4 veces al año
Idiomas
Inglés

1. J. La Bonte, J. Lebbos, A. Raja and P. Kirkpatrick, Infectious Diseases, Nat. Rev. Drug Discov. 3 (2004) S26–S32; https://doi.org/10.1038/nrd140910.1038/nrd1409Search in Google Scholar

2. B. Hughes, Tapping into combination pills for HIV, Nat. Rev. Drug Discov.8 (2009) 439–440; https://doi.org/10.1038/nrd291710.1038/nrd2917Search in Google Scholar

3. A. Raja, J. Lebbos and P. Kirkpatrick, Atazanavir sulphate, Nat. Rev. Drug Discov.2 (2003) 857–858; https://doi.org/10.1038/nrd123210.1038/nrd1232Search in Google Scholar

4. K. Geetha Bhavani, K. Bala Murali Krishna, N. Srinivasu, D. Ramachandran, N. V. V. S. S Raman and B. Hari Babu, Determination of genotoxic impurity in atazanavir sulphate drug substance by LC-MS, J. Pharm. Biomed. Anal.132 (2017) 156–158; https://doi.org/10.1016/j.jpba.2016.09.02510.1016/j.jpba.2016.09.025Search in Google Scholar

5. K. Watanabe, E. Varesio and G. Hopfgartner, Parallel ultra high pressure liquid chromatography-mass spectrometry for the quantification of HIV protease inhibitors using dried spot sample collection format, J. Chromatogr. B965 (2014) 244–253; https://doi.org/10.1016/j.jchromb.2014.05.00810.1016/j.jchromb.2014.05.008Search in Google Scholar

6. S. Colombo, N. Guignard, C. Marzolini, A. Telenti, J. Biollaz and L. A. Decosterd, Determination of the new HIV-protease inhibitor atazanavir by liquid chromatography after solid-phase extraction, J. Chromatogr. B810 (2004) 25–34; https://doi.org/10.1016/j.jchromb.2004.07.00810.1016/S1570-0232(04)00580-XSearch in Google Scholar

7. A. Loregian, S. Pagni, E. Ballarin, E. Sinigalia, S. G. Parisi and G. Palù, Simple determination of the HIV protease inhibitor atazanavir in human plasma by high-performance liquid chromatography with UV detection, J. Pharm. Biomed. Anal.42 (2006) 500–505; https://doi.org/10.1016/j.jpba.2006.04.03110.1016/j.jpba.2006.04.03116765009Search in Google Scholar

8. S. Dey, S. S. Patro, N. S. Babu, P. N. Murthy and S. K. Panda, Development and validation of a stability-indicating RP–HPLC method for estimation of atazanavir sulfate in bulk, J. Pharm. Anal.7 (2017) 134–140; https://doi.org/10.1016/j.jpha.2013.12.00210.1016/j.jpha.2013.12.002568686029404029Search in Google Scholar

9. C. H. Bhirud and S. N. Hiremath, Stability indicating RP-HPLC method for the determination of atazanavir sulphate in bulk and dosage form, Drug Invent. Today5 (2013) 81–86; https://doi.org/10.1016/j.dit.2013.05.00810.1016/j.dit.2013.05.008Search in Google Scholar

10. L. Else, V. Watson, J. Tjia, A. Hughes, M. Siccardi, S. Khoo and D. Back, Validation of a rapid and sensitive high-performance liquid chromatography–tandem mass spectrometry (HPLC–MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds, J. Chromatogr. B878 (2010) 1455–1465; https://doi.org/10.1016/j.jchromb.2010.03.03610.1016/j.jchromb.2010.03.03620427248Search in Google Scholar

11. M. Mirochnick, B. M. Best, A. M. Stek, E. V. Capparelli, C. Hu, S. K. Burchett, S. S. Rossi, E. Hawkins, M. Basar, E. Smith and J. S. Read, Atazanavir pharmacokinetics with and without tenofovir during pregnancy, JAIDS J. Acquir. Immune Defic. Syndr.56 (2011) 412–419; https://doi.org/10.1097/QAI.0b013e31820fd09310.1097/QAI.0b013e31820fd093312541921283017Search in Google Scholar

12. S. Goutelle, T. Baudry, M.-C. Gagnieu, A. Boibieux, J.-M. Livrozet, D. Peyramond, C. Chidiac, M. Tod and T. Ferry (on behalf of the Lyon HIV Cohort Study Group), Pharmacokinetic-pharmaco-dynamic modeling of unboosted atazanavir in a cohort of stable HIV-infected patients, Antimicrob. Agents Chemother.57 (2013) 517–523; https://doi.org/10.1128/AAC.01822-1210.1128/AAC.01822-12353592523147727Search in Google Scholar

13. C. S. Venuto, K. Mollan, Q. Ma, E. S. Daar, P. E. Sax, M. A. Fischl, A. C. Collier, K. Y. Smith, C. Tierney and G. D. Morse (on behalf of AIDS Clinical Trial Group Study A5202 Team), Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202, J. Antimicrob. Chemother.69 (2014) 3300–3310; https://doi.org/10.1093/jac/dku30310.1093/jac/dku303422877925159623Search in Google Scholar

14. D. K. Lloyd and J. Bergum, Application of quality by design (QbD) to the development and validation of analytical methods, in: Specification of Drug Substances and Products - Development and Validation of Analytical Methods (C. M. Riley, T. W. Rosanske and S. R. Rabel Riley, Eds.), Elsevier, Amsterdam 2014, pp. 29–72.10.1016/B978-0-08-098350-9.00003-5Search in Google Scholar

15. B. Kelley, M. Cromwell and J. Jerkins, Integration of QbD risk assessment tools and overall risk management, Biologicals44 (2016) 341–351; https://doi.org/10.1016/j.biologicals.2016.06.00110.1016/j.biologicals.2016.06.00127461127Search in Google Scholar

16. P. K. Sahu, N. R. Ramisetti, T. Cecchi, S. Swain, C. S. Patro and J. Panda, An overview of experimental designs in HPLC method development and validation, J. Pharm. Biomed. Anal.147 (2018) 590–611; https://doi.org/10.1016/j.jpba.2017.05.00610.1016/j.jpba.2017.05.00628579052Search in Google Scholar

17. M. de Matas, T. De Beer, S. Folestad, J. Ketolainen, H. Lindén, J. A. Lopes, W. Oostra, M. Weimer, P. Öhrngren and J. Rantanen, Strategic framework for education and training in Quality by Design (QbD) and process analytical technology (PAT), Eur. J. Pharm. Sci.90 (2016) 2–7; https://doi.org/10.1016/j.ejps.2016.04.02410.1016/j.ejps.2016.04.02427112991Search in Google Scholar

18. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline, Validation of Analytical Procedures: Pharmaceutical Development Q8 (R2), Current Step 4 version, August 2009; http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q8_R1/Step4/Q8_R2_Guideline.pdf; last access date March 10, 2018.Search in Google Scholar

19. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline, Validation of Analytical Procedures: Quality Risk Management Q9, Current Step 4 version, November 2005; http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q9/Step4/Q9_Guideline.pdf last access date March 10, 2018.Search in Google Scholar

20. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline, Validation of Analytical Procedures: Pharmaceutical Quality System Q10, Current Step 4 version, June 2008; http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q10/Step4/Q10_Guideline.pdf last access date March 10, 2018.Search in Google Scholar

21. J. Kochling, W. Wu, Y. Hua, Q. Guan and J. Castaneda-Merced, A platform analytical quality by design (AQbD) approach for multiple UHPLC-UV and UHPLC–MS methods development for protein analysis, J. Pharm. Biomed. Anal.125 (2016) 130–139; https://doi.org/10.1016/j.jpba.2016.03.03110.1016/j.jpba.2016.03.03127017571Search in Google Scholar

22. G. L. Reid, J. Morgado, K. Barnett, B. Harrington, J. Wang, J. Harwood and D. Fortin, Analytical Quality by Design (AQbD) in pharmaceutical development, Am. Pharm. Rev.16 (2013); https://www.americanpharmaceuticalreview.com/Featured-Articles/144191-Analytical-Quality-by-Design-AQbD-in-Pharmaceutical-Development/; last access date December 26, 2018.Search in Google Scholar

23. P. S. Sandhu, S. Beg, R. Kumar, O. P. Katare and B. Singh, Analytical QbD-based systematic bio-analytical HPLC method development for estimation of quercetin dihydrate, J. Liq. Chromatogr. Relat. Technol.40 (2017) 506–516; https://doi.org/10.1080/10826076.2017.132974410.1080/10826076.2017.1329744Search in Google Scholar

24. A. Dispas, H. T. Avohou, P. Lebrun, P. Hubert and C. Hubert, ‘Quality by Design’ approach for the analysis of impurities in pharmaceutical drug products and drug substances, Trends Anal. Chem.101 (2017) 24–33; https://doi.org/10.1016/j.trac.2017.10.02810.1016/j.trac.2017.10.028Search in Google Scholar

25. T. Schofield, D. Robbins and G. Miró-Quesada, Critical Quality Attributes, Specifications, and Control Strategy, in Quality by Design for Biopharmaceutical Drug Product Development (Eds. F. Jameel, S. Hershenson, M. A. Khan and S. Martin-Moe) /Advances in the Pharmaceutical Sciences Series, AAPS, Vol. 18 (Eds. D. J. A. Crommelin and R. A. Lipper)/Springer, New York, pp. 511–535.10.1007/978-1-4939-2316-8_21Search in Google Scholar

26. U. S. Food and Drug Administration (FDA), Center for drug evaluation and research (CDER), Reviewer Guidance-Validation of Chromatographic Methods, November 1994; https://www.fda.gov/downloads/Drugs/Guidances/UCM134409.pdf; last access date December 26, 2018Search in Google Scholar

27. What is peak tailing? Chromatogr. Today, August 8, 2014; https://www.chromatographytoday.com/news/autosamplers/36/breaking-news/what-is-peak-tailing/31253; last access date December 26, 2018.Search in Google Scholar

28. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline, Validation of Analytical Procedures: Text and Methodology, Q2 (R1), Current Step 4 version, November 2005; https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf; last access date March 10, 2018.Search in Google Scholar

29. T. Sharma, R. K. Khurana, A. Jain, O. P. Katare and B. Singh, Development of a validated liquid chromatographic method for quantification of sorafenib tosylate in the presence of stress-induced degradation products and in biological matrix employing analytical quality by design approach, Biomed. Chromatogr.32 (2018) e4169; https://doi.org/10.1002/bmc.416910.1002/bmc.416929244215Search in Google Scholar

30. N. K. Garg, G. Sharma, B. Singh, P. Nirbhavane and O. P. Katare, Quality by Design (QbD)-based development and optimization of a simple, robust RP-HPLC method for the estimation of methotrexate, J. Liq. Chromatogr. Relat. Technol.38 (2015) 1629–1637; https://doi.org/10.1080/10826076.2015.108740910.1080/10826076.2015.1087409Search in Google Scholar

31. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline, Validation of Analytical Procedures: Stability Testing of New Drug Substances and Products Q1A(R2), Current Step 4 version, February 2003; http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q1A_R2/Step4/Q1A_R2__Guideline.pdf; last access date March 10, 2018.Search in Google Scholar

32. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline, Validation of Analytical Procedures: Stability Testing: Photostability Testing of New Drug Substances and Products Q1B, Current Step 4 version, November 1996; http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q1B/Step4/Q1B_Guideline.pdf; last access date March 10, 2018.Search in Google Scholar

33. L. Zhang and S. Mao, Application of quality by design in the current drug development, Asian J. Pharm. Sci.12 (2017) 1–8; https://doi.org/10.1016/j.ajps.2016.07.00610.1016/j.ajps.2016.07.006703218332104308Search in Google Scholar

34. A. Loregian, S. Pagni, E. Ballarin, E. Sinigalia, S. G. Parisi and G. Palù, Simple determination of the HIV protease inhibitor atazanavir in human plasma by high-performance liquid chromatography with UV detection, J. Pharm. Biomed. Anal.42 (2006) 500–505; https://doi.org/10.1016/j.jpba.2006.04.03110.1016/j.jpba.2006.04.03116765009Search in Google Scholar

35. S. R. Chitturi, Y. S. Somannavar, B. G. Peruri, S. Nallapati, H. K. Sharma, S. R. Budidet, V. K. Handa and H. B. Vurimindi, Gradient RP-HPLC method for the determination of potential impurities in atazanavir sulfate, J. Pharm. Biomed. Anal.55 (2011) 31–47; https://doi.org/10.1016/j.jpba.2011.01.00210.1016/j.jpba.2011.01.00221316175Search in Google Scholar

36. M. K. V. V. N. Mantripragada, S. V. Rao, V. V. S. Nutulapati and B. P. V. Mantena, Simultaneous determination of impurities of atazanavir and ritonavir in tablet dosage form by using reversed-phase ultra performance liquid chromatographic method, J. Chromatogr. Sci.56 (2018) 270–284; https://doi.org/10.1093/chromsci/bmx11010.1093/chromsci/bmx11029300835Search in Google Scholar

37. N. Phung, K. Kuncze, H. Okochi, A. Louie, L. Z. Benet, I. Ofokotun, D. W. Haas, J. S. Currier, T. D. Chawana, A. N. Sheth, P. Bacchetti, M. Gandhi and H. Horng, Development and validation of an assay to analyze atazanavir in human hair via liquid chromatography/tandem mass spectrometry, Rapid Commun. Mass Spectrom. 32 (2018) 431–441; https://doi.org/10.1002/rcm.805810.1002/rcm.8058584850229315954Search in Google Scholar

Artículos recomendados de Trend MD

Planifique su conferencia remota con Sciendo